News Releases

News Releases

Synteract Experts To Address Challenges In Rare and Orphan Diseases at WODC US and Patients As Partners Conferences

RESEARCH TRIANGLE PARK, NC– March 7, 2019 – Experts from Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, will showcase its center of development in rare and orphan diseases at two conferences: Patients as Partners, March 11-12 in Philadelphia, and World Orphan Drug Congress (WODC USA), April 10-12, 2019 in Maryland, where it will also host a table top exhibit. Synteract experts will be on hand to discuss strategies for overcoming challenges in rare and orphan disease clinical trials, and the CRO’s Vice President of Rare And Orphan Diseases Lisa Dilworth, will present at both events.

Lisa Dilworth will speak during:

  • Patients as Partners, as she leads a session with Myasthenia Gravis patients and advocates to discuss patient engagement models in clinical trial development. She will also meet with attendees on advancing rare and orphan clinical trials.
  • WODC, as she leads a roundtable on “Meaningful endpoints – navigating the differences in what it means to patients, caregivers, physicians, and regulators during advanced therapies clinical development” on April 11 at 2:30 pm. She can meet with attendees on advancing rare and orphan clinical trials before and after that time.

Synteract has conducted more than 130 clinical trials in rare and orphan diseases in the past five years alone. With its focused center of development in rare and orphan diseases, it offers high-quality project management, full-service capabilities and international presence for clinical trials that have never been done before.

Attendees and investigators can schedule an appointment with Synteract executives by contacting Alberto Bryan: alberto.bryan@synteract.com

About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. With 800 employees across 21 countries, Synteract is an innovative CRO supporting biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter

# # #
CONTACT:
Hilary McCarthy
hilary@clearpointagency.com
508-829-2543

x

Submit RFI / RFP

..
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required